Note purchase agreement and consulting agreement with G FarmaLabs Limited (Details Narrative) - USD ($) |
12 Months Ended | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 27, 2021 |
Mar. 04, 2019 |
Mar. 17, 2017 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Oct. 31, 2022 |
Sep. 30, 2022 |
Aug. 31, 2022 |
Aug. 30, 2022 |
Nov. 04, 2020 |
Apr. 22, 2019 |
|
Two promissory notes [Member] | |||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||||
Debt instrument, face amount | $ 1,166,570 | ||||||||||
G FarmaLabs Limited [Member] | |||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||||
Notes receivable bad debt reserve | $ 1,039,501 | $ 1,043,531 | |||||||||
Notes receivable related party | 0 | 0 | |||||||||
Other income | $ 3,550 | $ 2,000 | |||||||||
G FarmaLabs Limited [Member] | Mentor partner I [Member] | |||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||||
Cost of impounded assets | $ 427,804 | ||||||||||
Notes purchase agreement [Member] | G FarmaLabs Limited [Member] | |||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||||
Debt instrument, face amount | $ 990,000 | $ 500,000 | |||||||||
Debt instrument, interest rate, stated percentage | 7.42% | ||||||||||
Debt instrument, maturity date | Apr. 15, 2022 | ||||||||||
Debt instrument, periodic payment | $ 10,239 | ||||||||||
Settlement agreement and mutual release [Member] | G Farma [Member] | |||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||||
Liability for unpaid claims and claims adjustment expense schedule, discussion | The Settlement Agreement requires the G Farma Settlors to pay the Company an aggregate of $500,000 plus interest, payable monthly as follows: (i) $500 per month for 12 months beginning on September 5, 2021, (ii) $1,000 per month for 12 months beginning September 5, 2022, (iii) $2,000 per month for 12 months beginning September 5, 2023, and (iv) increasing by an additional $1,000 per month on each succeeding September 5th thereafter, until the settlement amount and accrued unpaid interest are paid in full. Interest on the unpaid balance shall initially accrue at the rate of 4.25% per annum, commencing February 25, 2021, compounded monthly, and shall be adjusted on February 25th of each year to equal the Prime Rate as published in the Wall Street Journal plus 1% | ||||||||||
Liability for unpaid claims and claims adjustment expense, adjustments | $ 2,000,000 | ||||||||||
Settlement agreement and mutual release [Member] | G Farma Settlors [Member] | |||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||||
Notes receivable related party | $ 1,045,051 | ||||||||||
Liability for unpaid claims and claims adjustment expense schedule, discussion | The Settlement Agreement requires the G Farma Settlors to pay the Company an aggregate of $500,000 plus interest, payable monthly as follows: (i) $500 per month for 12 months beginning on September 5, 2021, (ii) $1,000 per month for 12 months beginning September 5, 2022, (iii) $2,000 per month for 12 months beginning September 5, 2023, and (iv) increasing by an additional $1,000 per month on each succeeding September 5th thereafter, until the settlement amount and accrued unpaid interest are paid in full. Interest on the unpaid balance shall initially accrue at the rate of 4.25% per annum, commencing February 25, 2021, compounded monthly, and shall be adjusted on February 25th of each year to equal the Prime Rate as published in the Wall Street Journal plus 1%. | ||||||||||
Liability for unpaid claims and claims adjustment expense, net | $ 500,000 | $ 500,000 | $ 500,000 | $ 500,000 | $ 500,000 | ||||||
Liability for unpaid claims and claims adjustment expense, adjustments | $ 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | |||||||
Liability for accrued unpaid interest | $ 2,000,000 | $ 2,000,000 | $ 2,000,000 |